PUBLISHER: Grand View Research | PRODUCT CODE: 1870008
PUBLISHER: Grand View Research | PRODUCT CODE: 1870008
The global allergy diagnostics and therapeutics market size was estimated at USD 34.42 billion in 2024 and is projected to reach USD 78.00 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Some of the major factors driving the market are rising incidence of allergies, advancements in technology and launch of new products, and high adoption of immunotherapy drugs.
In November 2022, the Global Allergy and Airways Patient Platform reported that approximately 30-40% of people today have one or more allergies, and the number of people with allergies has been increasing over the past 20 years. Furthermore, changing lifestyle and growing pollution are some of the key factors contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs namely immunotherapy, which solves unmet patient needs, is expected to boost market growth over the forecast period. For instance, in February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure due to more than one food. Also, Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
The rising prevalence of allergies is one of the important reasons driving the growth of the allergy therapeutics market over the predicted period. High risk factors for chronic respiratory disorders include increased exposure to outdoor and indoor air pollution, as well as occupational exposure. Allergies are far more common in cities than in rural areas, owing to increased exposure to environmental contaminants due to industrial activity and urbanization.
According to statistics published by WHO in January 2024, around 1 in 4 children and 1 in 3 adults have a seasonal allergy in the U.S. Nearly 6% of children and adults in the U.S. suffer from a food allergy, with the rate being highest among black, Asian, and Hispanic individuals. Similarly, as per data from the Asthma and Allergy Foundation of America, in 2021, in the U.S., about 81 million people were diagnosed with seasonal allergic rhinitis, representing around 26% affected adults and 19% affected children.
Increasing demand for IVD testing is likely to drive the allergy diagnostics and therapeutics market over the forecast period. In vitro blood tests are used to diagnose food, inhalation, skin, and medication allergies. These tests have several advantages, including the fact that they are minimally invasive, cost-effective, and user-friendly, which is expected to provide profitable growth prospects in this market. Furthermore, the development of low-cost and effective in vitro diagnostic tests for allergy detection, increased lab automation, and an increase in reagent rental agreements are all projected to contribute to market expansion in the future years.
Global Allergy Diagnostics and Therapeutic Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2030. For this report, Grand View Research has segmented the global allergy diagnostics & therapeutics market based on type, allergen type, test type, and region: